Chimeric antigen receptors (CARs) have found clinical success in B cell malignancies, but a dearth of potential targets limits their wider clinical application, especially in solid tumours. Here, we describe the development of an anti-annexin A2 CAR,...
Authors: Leonard Leong , Heng Liang Tan , Simeon Cua , Kylie Su Mei Yong , Qingfeng Chen , Andre Choo
SST Peer Reviewed